This is the protocol for a review and there is no abstract. The objectives are as follows:, To summarise data from trials on the effects and safety of deferiprone as an iron chelating agent in people with transfusion-dependent thalassaemia., To compare the safety and effectiveness of deferiprone for thalassaemia with desferrioxamine., Deferirpone can be administered according to different dose schedules. If trials are identified where this is the case, the different schedules will be compared with regards to the listed outcomes